Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shares were up 5.3% during mid-day trading on Monday . The company traded as high as $72.48 and last traded at $71.69, with a volume of 630,413 shares changing hands. The stock had previously closed at $68.08.

A number of research analysts have recently issued reports on ALNY shares. Jefferies Group reaffirmed a “buy” rating and set a $80.00 price target (down from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, May 22nd. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, April 14th. Zacks Investment Research downgraded Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. Finally, Leerink Swann lowered their target price on Alnylam Pharmaceuticals from $120.00 to $107.00 and set an “outperform” rating on the stock in a report on Tuesday, May 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $115.75.

The firm’s market capitalization is $6.04 billion. The stock has a 50 day moving average of $61.74 and a 200-day moving average of $63.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.16. The business earned $7.30 million during the quarter, compared to analyst estimates of $7.79 million. The business’s revenue was down 60.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Several institutional investors recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 9.0% in the fourth quarter. Vanguard Group Inc. now owns 5,048,221 shares of the biopharmaceutical company’s stock valued at $475,241,000 after buying an additional 416,709 shares during the period. BlackRock Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 8.2% in the fourth quarter. BlackRock Advisors LLC now owns 179,529 shares of the biopharmaceutical company’s stock valued at $16,901,000 after buying an additional 13,612 shares during the period. Jennison Associates LLC boosted its position in shares of Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Jennison Associates LLC now owns 1,489,541 shares of the biopharmaceutical company’s stock valued at $140,225,000 after buying an additional 7,296 shares during the period. Advisors Asset Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares during the period. Finally, Gulf International Bank UK Ltd boosted its position in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the period.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.